Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15846863 | 0.94 | KDM4A (0.40) | TDP1KDM4AKDM4CKISS1REPHX1 | |
| SCHEMBL1507142 | 0.86 | — | — | |
| SCHEMBL1127682 | 0.86 | CA12 (0.30) | KDM4AKDM4C | |
| Chloromethane SCHEMBL16430276 | 0.83 | TDP1 (0.35) | TDP1 | |
| SCHEMBL337280 | 0.80 | KDM4A (0.38) | TDP1KDM4AKDM4CKISS1REPHX1 | |
| SCHEMBL4861564 | 0.79 | CYP2C19 (0.41) | TDP1 | |
| SCHEMBL3933556 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL8005993 | 0.78 | KDM4A (0.41) | TDP1KDM4AKDM4CKISS1REPHX1 | |
| Dimethylamine SCHEMBL21409716 | 0.78 | CES1 (0.42) | TDP1 | |
| SCHEMBL29286894 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235390-A1 | Composition and Process for Treating a Disorder in the Oral Cavity of a Mammal | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2025-07-24 | — | — | US | claimed |
| EP-3534867-B1 | MEDICAL COMPOSITION CONTAINING GUANIDINYL-CONTAINING POLYMER(S) AND CARRAGEENANE(S) | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-06-04 | — | — | EP | claimed |
| EP-4419062-A1 | COMPOSITION AND PROCESS FOR TREATING A DISORDER IN THE ORAL CAVITY OF A MAMMAL | Solventum Intellectual Properties Company (US) | 2024-08-28 | — | — | EP | claimed |
| US-11766386-B2 | Medical composition containing guanidinyl-containing polymer(s) and carrageenane(s) | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-09-26 | — | — | US | claimed |
| WO-2023067453-A1 | COMPOSITION AND PROCESS FOR TREATING A DISORDER IN THE ORAL CAVITY OF A MAMMAL | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-04-27 | — | — | WO | claimed |
| EP-0118327-B1 | CATIONIC LATICES FROM CONJUGATED DIENES | RHONE-POULENC CHIMIE (FR) | 1987-04-22 | — | — | EP | claimed |
| US-12630582-B2 | Method for biomaterial purification and kits thereof | Life Technologies Corporation (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250235390-A1 | Composition and Process for Treating a Disorder in the Oral Cavity of a Mammal | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2025-07-24 | — | — | US | disclosed |
| EP-3534867-B1 | MEDICAL COMPOSITION CONTAINING GUANIDINYL-CONTAINING POLYMER(S) AND CARRAGEENANE(S) | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-3534866-B1 | METHOD OF DENTAL RETRACTION WITH COMPOSITION WITH GUANIDINYL-CONTAINING POLYMER | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250082440-A1 | Composition for Isolating Tissue | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2025-03-13 | — | — | US | disclosed |
| EP-4419062-A1 | COMPOSITION AND PROCESS FOR TREATING A DISORDER IN THE ORAL CAVITY OF A MAMMAL | Solventum Intellectual Properties Company (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-4380494-A1 | COMPOSITION FOR ISOLATING TISSUE | Solventum Intellectual Properties Company (US) | 2024-06-12 | — | — | EP | disclosed |
| US-6877851-B2 | Ink set for ink jet recording, ink jet recording process, and recorded matter | SEIKO EPSON CORPORATION (JP) | 2005-04-12 | — | — | US | disclosed |
| EP-1487882-A1 | BASE POLYMER OBTAINED BY HYDROGENATION | Stockhausen GmbH (DE) | 2004-12-22 | — | — | EP | disclosed |
| US-20040239738-A1 | Ink set for ink jet recording, ink jet recording process, and recorded matter | SEIKO EPSON CORPORATION | 2004-12-02 | — | — | US | disclosed |
| WO-2003080682-A1 | BASE POLYMER OBTAINED BY HYDROGENATION | STOCKHAUSEN GMBH (DE) | 2003-10-02 | — | — | WO | disclosed |
| EP-1237958-A1 | METHOD FOR PRODUCING WATER-SOLUBLE POLYMERS, COMPRISING OLIGOALKYLENE-IMINE SIDE CHAINS | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001036500-A1 | METHOD FOR PRODUCING WATER-SOLUBLE POLYMERS, COMPRISING OLIGOALKYLENE-IMINE SIDE CHAINS | BASF AKTIENGESELLSCHAFT (DE) | 2001-05-25 | — | — | WO | disclosed |
| EP-0293087-A1 | Production of electrically conductive ethylene copolymer moldings | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630582-B2 | Method for biomaterial purification and kits thereof | CD68, FIBP, BMP2 | TDP1 661/4885KDM4A 4376/4885KDM4C 3429/4885 |
| US-11766386-B2 | Medical composition containing guanidinyl-containing polymer(s) and carrageenane(s) | GANC, GMPS, MGAM | TDP1 2728/4885KDM4A 2770/4885KDM4C 2256/4885 |
| US-20250235390-A1 | Composition and Process for Treating a Disorder in the Oral Cavity of a Mammal | GSDMD, PIGS, GANC | TDP1 1508/4885KDM4A 3395/4885KDM4C 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.